euro diagnostica - martin salden 24022011
TRANSCRIPT
Reuma-diagnostiek in beweging
Martin Salden
Euro-Diagnostica
AB
Euro-Diagnostica
ABDBWieslab AB
Wieslab BV Wieslab XX
ED-Group:
Draupnir
ED-Group
NordicGroup
PPLGroup
DraupnirServices B.V.
Draupnir
PolyPeptide Group
• One of the world's leading groups specialized in the industrial scale manufacture of custom and generic peptides for therapeutic (and cosmetic) applications.
• Manufacturing facilities in Denmark, Sweden, France, Czech Republic, USA and India.
Nordic Group
• The Nordic Group is a fully-integrated, pan-European Pharmaceutical Group.
• Nordic Group focuses on two specialized segments of the Pharmaceutical market:- Marketing & Sales of specialty (generic)
pharmaceuticals; - Specialized Pharmaceutical Services focusing on
Product Development, Manufacturing, supplyLogistics and Regulatory activities.
Euro-Diagnostica Group
• Euro-Diagnostica focuses on the diagnosis and monitoring of specific diseases.
• Euro-Diagnostica develops, manufactures and markets complete diagnostic kits and reagents for use in special medical areas like autoimmune diseases and Rheumatology.
• The Group operates from establishments in Nijmegen (The Netherlands) and Malmö (Sweden)
Formation of the company
• 1992: Euro-Diagnostica established by a merger of– Ferring Diagnostica, SE– BioCarb Diagnostics, SE– Euro-Diagnostics, NL– Medscand Diagnostics-MILAB, SE
Strategic Mergers and Acquisitions
• 2004: Acquisition of Wieslab AB – Well established trade name– Added further competence in protein chemistry– Key competence in developing ANCA tests – Scandinavia`s leading private autoimmune laboratory
EuroDiagnostica/Wieslab• Employees
– Malmö, E-DEON Sweden, 70 employees – Nijmegen, Mercator 3 building,The Netherlands, 6 employees
World Wide Distribution Network
• Key Markets– North America– Europe– Japan
– Own distribution of products in the Nordic countries, Benelux, UK and Germany
Cutting Edge Diagnostics
• Euro-Diagnostica is the leader in the development of unique – ANCA tests – Vasculitis diagnosis– Anti-CCP2 based tests – Rheumatoid Arthritis diagnosis
anti-CCP2 ELISA
• The ultimate serological marker for diagnosis of Rheumatoid Arthritis
– Specific – Allows early detection of RA– Sensitive – Prognostic marker
CCPoint® anti-CCP point-of-care test
• The first POC test for anti-CCP– Enables near-patient diagnosis of RA– Enables rapid diagnosis – rapid treatment– Specific and sensitive as ELISA
• Wieslab® SSA p200 ELISA• Wieslab® Complement ELISA
CCP assay based on discovery of Prof van Venrooij
• STW agreement– IP protection. Prepare to defend ?
• Product development– Core technology.– BioBank to validate product.
• Marketing & Sales– ED brand, protect product name CCP!– OEM, no competitive products!– Inventor best promoter of product
• Personal click
Add 5 drops of chase bufferAdd 1 drop of blood
Read the results after 10 min
Open the flip-up after 30 sec
Areas of clinical competence
• Systemic vasculitidies. Rapidly progressing glomerulonehritis.
• Reference laboratory for ANCA testing• Complete range of autoimmune analyses
Service for clients
• Acute testing for ANCA and anti-GBM daily 7/24• Support and interpretation of test results• Analysis packages according to client’s wishes
24 hour service for ANCA and anti-GBM• Rapidly progressing glomerulonephritis• Acute reno-pulmonary syndromes• Qualitative testing of PR3-ANCA, MPO-ANCA and anti-GBM.
High sensitivity.• Results within one hour from the sample reaching the laboratory• Positive results are confirmed by quantitative ELISA the
following day